B
BigHat Biosciences
Protein therapeutics company that develops an antibody design platform guided by artificial intelligence
About BigHat Biosciences
BigHat Biosciences is a biotech startup that operates in the field of antibody therapies. The company uses machine learning and synthetic biology to design safer and more effective treatments for patients suffering from a variety of challenging diseases. Their primary focus is on diseases that are difficult to treat, such as certain types of infections and cancers.
Read full description
BigHat Biosciences' business model revolves around their proprietary Milliner platform. This platform combines a synthetic biology-based wet lab with advanced machine learning technologies to create a comprehensive antibody discovery and engineering platform. The Milliner platform allows for the synthesis, purification, and full characterization of hundreds of recombinant antibodies in a single weekly workcell. This high-speed process results in the development of better antibodies at a faster rate.
The company serves a broad range of clients, including healthcare providers and patients. They operate in the biotech market, specifically in the area of antibody therapies. The company generates revenue by developing and selling their antibody therapies.
BigHat Biosciences is based outside of San Francisco and has raised over $100 million in funding from top investors. Despite being a high-performance company, BigHat Biosciences also emphasizes work-life balance and a family-friendly culture.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Mateo, United States
- Employees
- 95
- Open positions
- 9
- Dealroom signal
- 65.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Antibodies, Core AI, Synthetic Biology, Biotech and Pharma, AI Drug Discovery, Hard Tech, AI Applications, proteomics
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2022 | $75M | $300M | 8VC · Amgen Ventures · Quadrille Capital · Gaingels | ↗ |
| SERIES AOther financing | Feb 2021 | $19M | $76M | Innovation Endeavors · AME Cloud Ventures · 8VC · Andreessen Horowitz | — |
Growth signals
Latest recorded traffic for BigHat Biosciences is 9.8K monthly website visits, down 18.3% over the last three months. BigHat Biosciences's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
8VC
National Institute of Standards and Technology
Series A9 investors entered at this stage
Andreessen Horowitz
Innovation Endeavors
AME Cloud Ventures
Section 32
Amgen Ventures
Quadrille Capital
Gaingels
GRIDS Capital
Bristol-Myers Squibb
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BigHat Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BigHat Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.